Occurrence, duration, and grade of ICANS in infused subjects (n = 19)
| UPN . | Neurotoxicity . | Start day # . | Duration (d) . | Grade . | Comments . |
|---|---|---|---|---|---|
| 01 | No | — | — | 0 | — |
| 02 | No | — | — | 0 | — |
| 03 | No | — | — | 0 | — |
| 04 | No | — | — | 0 | — |
| 05 | No | — | — | 0 | — |
| 06 | Yes | 6 | 14 | 2 | Confusion |
| 07 | No | — | — | 0 | — |
| 08 | Yes | 3 | 2 | 1 | Confusion |
| 09 | No | — | — | 0 | — |
| 10 | No | — | — | 0 | — |
| 11 | No | — | — | 0 | — |
| 12 | No | — | — | 0 | — |
| 13 | Yes | 8 | 4 | 2 | Delirium |
| 15 | Yes | 5 | 1 | 1 | Confusion |
| 16 | No | — | — | 0 | — |
| 17 | Yes | 2 | 8 | 4 | Delirium, tremor, facial droop, dysphagia, expressive dysphasia |
| 18 | No | — | — | 0 | — |
| 19 | No | — | — | 0 | — |
| 20 | No | — | — | 0 | — |
| UPN . | Neurotoxicity . | Start day # . | Duration (d) . | Grade . | Comments . |
|---|---|---|---|---|---|
| 01 | No | — | — | 0 | — |
| 02 | No | — | — | 0 | — |
| 03 | No | — | — | 0 | — |
| 04 | No | — | — | 0 | — |
| 05 | No | — | — | 0 | — |
| 06 | Yes | 6 | 14 | 2 | Confusion |
| 07 | No | — | — | 0 | — |
| 08 | Yes | 3 | 2 | 1 | Confusion |
| 09 | No | — | — | 0 | — |
| 10 | No | — | — | 0 | — |
| 11 | No | — | — | 0 | — |
| 12 | No | — | — | 0 | — |
| 13 | Yes | 8 | 4 | 2 | Delirium |
| 15 | Yes | 5 | 1 | 1 | Confusion |
| 16 | No | — | — | 0 | — |
| 17 | Yes | 2 | 8 | 4 | Delirium, tremor, facial droop, dysphagia, expressive dysphasia |
| 18 | No | — | — | 0 | — |
| 19 | No | — | — | 0 | — |
| 20 | No | — | — | 0 | — |
ICANS, Immune effector Cell Associated Neurotoxicity Syndrome.